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Introduction
In response to sequential estrogen and progesterone
secretion from the ovary, the endometrium prolifer-
ates and then differentiates to become receptive to
the embryo.1 Significant elongation, branching, and
dilatation of endometrial vessels are induced by coor-
dinated action of estrogen and progesterone, thereby
providing adequate blood supply to the receptive en-
dometrium. In women with unexplained subfertility,
endometrial and subendometrial vascularity have been
found to be significantly reduced.2 The junctional zone
between the endometrium and myometrium, called
the subendometrial zone, is rich in blood supply and
plays an important role in the implantation process.3
However, the effects of estrogen and progesterone on
the hemodynamics of the subendometrial zone have
not been studied.
Most of the studies examining uterine perfusion
have applied pulsed wave Doppler.4,5 Spiral arteries,
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terminal branches of the uterine arteries that supply
the subendometrial region, have low flow rates and
tortuous vasculature, making it difficult to accurately
measure spiral artery blood flow using pulsed wave
Doppler.6 In contrast to pulsed wave Doppler, which
analyzes the frequency shift of blood velocity infor-
mation, the recently developed power Doppler ultra-
sound uses the amplitude component of the signals
received to represent the number of moving blood
cells.7 Power Doppler ultrasound has been found to 
be superior to pulsed wave Doppler in situations of
low blood flow, because it is more sensitive, less
angle-dependent and not susceptible to aliasing. In
combination with 3-dimensional (3D) ultrasound,
power Doppler provides a unique tool to accurately
quantify subendometrial blood flow.
Vascular endothelial growth factor (VEGF), an iden-
tified diffusible angiogenic factor, is emerging as an
important factor for neovascularization of the repro-
ductive tract.8 It acts through several tyrosine kinase
receptors, inducing both proliferation of endothelial
cells and vascular permeability.9 VEGF is one of the key
angiogenic factors in the endometrium, where VEGF
expression is upregulated in the mid-luteal phase.10 This
suggests that a concerted action of estrogen and pro-
gesterone is necessary for maximal VEGF production.
The purpose of this study was to examine the roles
of estrogen and progesterone in endometrial angio-
genesis, using in vivo and in vitro approaches. Early
postmenopausal women taking cyclic estrogen and
progestin were recruited for serial examinations of
endometrial hemodynamics by 3D power Doppler
angiography (3D-PDA), since these patients had no
intrinsic fluctuations of ovarian steroid secretion and
their endometrium would still be responsive to hor-
monal treatments. Then, we analyzed the effects of
estrogen and progesterone on VEGF production from
Ishikawa endometrial epithelial cells (EEC), which are
positive for estrogen and progesterone receptors (ER
and PR). Our data may help clarify the physiologic roles
of estrogen and progesterone in endometrial angio-
genesis that are important for embryo implantation.
Methods
Experimental design and recruitment of cases
We recruited postmenopausal women who had under-
gone menopause no more than 3 years previously and
begun to take hormone treatment for alleviation of
vasomotor symptoms and prevention of osteoporosis
between December 2005 and November 2006. In-
formed consent was obtained from all participating
patients. The menopausal status was confirmed by
serum levels of estradiol and follicle-stimulating hor-
mone, i.e. estradiol <25pg/mL and follicle-stimulating
hormone > 20 mIU/mL. Patients with fibroids mea-
suring > 3 cm in diameter, endometrial lesions, or
adnexal abnormalities were excluded from the study.
The recruited cases received cyclic hormone therapy,
Sevina (Synmosa Biopharma, Taipei, Taiwan), to relieve
menopausal symptoms and prevent osteoporosis. One
course of Sevina treatment consists of 2 mg estradiol
valerate (estrogen) daily from the 1st day to the 11th day,
and 2 mg estradiol valerate plus 1 mg norethisterone
acetate (progestin) daily from the 12th to 21st day. All
cases received transvaginal ultrasonography and 3D-
PDA on the day before Sevina treatment (phase 0),
on days 10–11 of Sevina treatment (phase E), and on
days 18–20 of Sevina treatment (phase E + P).
Ultrasound data acquisition and analysis
Data were acquired using a GE Voluson 730 Expert
ultrasound system (GE Healthcare, Zipf, Austria)
equipped with a 2.8–10-MHz transvaginal transducer.
Identical fixed preinstalled power Doppler ultrasound
settings were used in all cases: frequency 3–9 MHz,
pulse repetition frequency 0.6 kHz, gain −5.0, wall
motion filter “low 1”. All scans were conducted by a
single ultrasonographer (L.H. Chen). Each case was
scanned in the supine position with knees flexed and
hips abducted. A longitudinal view of the endometrial
cavity was acquired and the volume mode entered.6
Then, the resultant truncated sector defining the area
of interest was adjusted, and the sweep angle set to
75° to ensure that the entire endometrium and suben-
dometrium were included. A 3D data set was then
obtained. Analysis of stored ultrasound volumes was
done using the VOCALTM (Virtual Organ Computer-
aided AnaLysis) imaging program. Endometrial vol-
ume and subendometrial power Doppler flow indices
were calculated. Three vascular indices were generated,
i.e. vascularization index, flow index and vasculariza-
tion flow index.11 Vascularization index represents
the ratio of color voxels to all voxels in the region of
interest and reflects the density of vessels in the vol-
ume analyzed. Flow index is the mean intensity of all
the power Doppler voxels in the volume of interest
(the sum of the weighted color voxels divided by the
number of all color voxels in the region analyzed) and
indicates the energy reflected from the blood corpus-
cles in the vessels of the volume. Vascularization flow
index is the sum of the weighted color voxels divided
by all voxels in the region analyzed and shows both
the density of vessels and the density of blood corpus-
cles in the vessels. Subendometrial flow indices were
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obtained by applying a 5-mm shell outside the endo-
metrial contour and analyzing the shell functions of
the VOCAL.
Cell culture
Ishikawa (ECACC No. 99940201) EEC line was pur-
chased from the European Collection of Cell Cultures
(ECACC; Salisbury, UK) through the Union Biomed
Corporation (Taipei, Taiwan). Expression of ER and
PR are positive in Ishikawa cells.12 Cells were cultured
at 5% CO2 and 37°C in minimum essential medium
(MEM; Life Technologies, Grand Island, NY, USA)
supplemented with 10% fetal calf serum (FCS) (Bio-
logical Industries, Kibbutz Beit Haemek, Israel). The
cells were subcultured every 2 days by trypsinization
(trypsin-EDTA solution; Life Technologies). For exper-
iments on the effects of estradiol and progesterone,
cells were cultured in a phenol-red-free MEM-alpha
medium (Life Technologies) supplemented with 10%
charcoal/dextran stripped FCS.
VEGF measurement
Cells were seeded at 1 × 104/100 μL/well in 96-well
plates. After overnight incubation, different concen-
trations of 17-β-estradiol and progesterone (Sigma,
St Louis, MO, USA) were added to each well. After
24 hours of treatment, the supernatants were collected
and stored at −70°C for future analysis. The concen-
trations of VEGF in these samples were measured
using the VEGF immunoassay Quantikine kit (R&D
Systems, Minneapolis, MN, USA). An equal volume
of each sample was added to each well of a 96-well
ELISA plate that was precoated with an anti-VEGF
antibody and then incubated for 2 hours at room
temperature. The plate was then washed with buffer 
3 times, followed by incubation for another 2 hours at
room temperature with a peroxidase-conjugated sec-
ondary antibody. After washing 3 times with buffer,
the substrate solution was added and the color was
developed for 20 minutes at room temperature. Sub-
sequently, the reaction was stopped by adding stop
solution, and the optical density of the samples was read
at 450 nm with correction of wavelength at 540 nm.
Statistical analysis
Data were expressed as mean ± standard error of the
mean, and analyzed by repeated-measures analysis of
variance (ANOVA) for the ultrasound data and 1-way
ANOVA for the VEGF data, using SAS (SAS Institute
Inc., Cary, NC, USA), followed by Fisher’s post hoc least
significant difference test. A p value < 0.05 was desig-
nated as statistically significant. All analyses were per-
formed on a Pentium IV-based personal computer.
Results
Effects of estrogen and progestin on endometrial
volume
A total of 6 patients were recruited. The mean age
was 54 years. Mean parity was 2. Average time after
menopause was 1.8 years. Before hormone treatment,
mean serum estradiol, follicle-stimulating hormone,
and luteinizing hormone were 16.3pg/mL, 46.8mIU/
mL, and 52.4 mIU/mL, respectively. Endometrial
volume, as measured by 3D ultrasound, was signifi-
cantly increased after treatment with estrogen for
10–11 days (phase E) compared with that before treat-
ment (phase 0). After treatment with estrogen for 11
days and estrogen plus progestin for another 7–9 days
(phase E+P), the endometrial volume remained as high
as that in phase E and was significantly higher than
that in phase 0 (Figure 1; p < 0.05 between phase E and
phase 0, p < 0.05 between phase E + P and phase 0,
p > 0.05 between phase E and phase E + P; n = 6).
Effects of estrogen and progestin on
subendometrial vascular flow
3D-PDA is a very useful tool to quantify hemodynam-
ics in low-blood-flow subendometrial vessels because
it is very sensitive. As shown in Figures 2A and 2B,
the density of subendometrial vessel volumes (vascu-
larization index) was significantly increased in phase
E + P compared with those in phase 0 and phase E
(p < 0.05 between phase E + P and phase 0, p < 0.05
between phase E + P and phase E; n = 6). Further-
more, the flow index and vascularization flow index
were significantly higher in phase E + P than in phase 0
(Figures 2C and 2D; p < 0.05 between phase E + P





















Figure 1. Endometrial volume in different phases of hormone
treatment. Phase 0 = before hormone treatment. Phase E = estro-
gen phase of hormone treatment. Phase E + P = estrogen plus
progestin phase of hormone treatment. *p < 0.05 compared to
phase 0 (n = 6).
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Effects of estrogen and progesterone on VEGF
secretion from EEC
Since VEGF is the main angiogenic factor in the
endometrium,10 the effects of estrogen and proges-
terone on VEGF secretion from Ishikawa EEC were
examined. Ishikawa EEC were cultured in the pres-
ence or absence of 17-β-estradiol and progesterone
for 24 hours, followed by collection of the super-
natants for VEGF measurements. While treatment of
cells with 17-β-estradiol had little enhancing effect on
VEGF production, progesterone significantly increased
VEGF secretion from EEC (Figure 3; p > 0.05 be-
tween the 17-β-estradiol-only group and vehicle-treated
control group, p < 0.05 between the progesterone-
only group and vehicle-treated control group; n = 5).
Treatment of cells with 17-β-estradiol plus proges-
terone also significantly enhanced VEGF secretion as
compared with the vehicle-treated control group, but
the enhancing effect of 17-β-estradiol plus proges-
terone on VEGF secretion was similar to that of pro-
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Figure 2. Three-dimensional power Doppler analysis of subendometrial blood flow in different phases of hormone treatment. Phase 0 =
before hormone treatment. Phase E = estrogen phase of hormone treatment. Phase E + P = estrogen plus progestin phase of hormone
treatment. (A) Representative ultrasound images. Arrow indicates subendometrial region. (B) Vascularization index. (C) Flow index. 
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Figure 3. Effects of 17-β-estradiol (E2) and progesterone (P4) 
on vascular endothelial growth factor (VEGF) production in
endometrial epithelial cells. Cells were treated with or without E2
and P4 for 24 hours, followed by determination of VEGF concen-
trations in the supernatants. 100% VEGF production was defined
as the level of VEGF production in cultures treated with vehicles
for 24 hours. *p < 0.05 compared with vehicle-treated controls
(n = 5).
plus progesterone group and vehicle-treated control
group, p > 0.05 between the 17-β-estradiol plus pro-
gesterone group and progesterone-only group; n = 5).
Discussion
Establishment and maintenance of the vasculature of
the endometrium is one of the most critical determi-
nants of pregnancy outcomes.13 However, the roles of
estrogen and progesterone in endometrial angiogene-
sis remain controversial.14 Here, we demonstrated that
estrogen treatment (phase E) could increase endome-
trial volume in early postmenopausal women and the
addition of progesterone (phase E + P) did not further
increase endometrial volume. In contrast, subendome-
trial vascularity and blood flow were significantly in-
creased in phase E + P but not in phase E, compared
with those in phase 0. Furthermore, VEGF production
in ER- and PR-positive Ishikawa EEC was enhanced
by progesterone but not by 17-β-estradiol. These re-
sults suggest that endometrial proliferation is stimu-
lated by estrogen and endometrial angiogenesis is
induced by progesterone.
Estrogen acts as a cell mitogen, and progesterone,
in contrast, acts as a differentiation factor.15 Further-
more, estrogen induces PR expression in the endo-
metrium.16 In this study, we demonstrated that
progesterone could enhance VEGF production in
PR-positive Ishikawa EEC, and that subendometrial
vascularity and blood flow were significantly increased
in phase E + P of cyclic hormone therapy. We proposed
that after priming of endometrium with estrogen in
the first 11 days of hormone treatment (phase E), PR
expression in the endometrium could be induced, and
therefore, the addition of progestin in the subsequent
phase E + P significantly increased endometrial VEGF
production, vascularity, and blood flow. Our concept
was supported by a previous study showing that human
endometrium was more responsive to progestin in the
late proliferative phase when the endometrium had been
exposed to endogenous estradiol for several days.17
To investigate endometrial angiogenesis, many
radiographic tools have been introduced. Recently,
functional imaging by magnetic resonance imaging has
improved multiparametric measurement of endometrial
angiogenesis in mice.18 In addition, 18F-fluoro-deoxy-
glucose uptake in positron emission tomography has
been applied to measure endometrial blood flow.19
Furthermore, endometrial blood flow has been deter-
mined by the clearance of radiolabeled xenon-133
following its instillation into the uterine cavity.20 The
aforementioned radiographic tools, however, require
intravenous or intrauterine injection of chemicals. 
In contrast, 3D-PDA represents an appropriate, inform-
ative and noninvasive tool for the assessment and
quantification of endometrial hemodynamics.11 3D-
PDA has been applied to predict endometrial cancer21
and assess uterine receptivity.2,22 In the present study,
we aimed to study the effects of estrogen and proges-
terone on endometrial hemodynamics. Early post-
menopausal women were recruited because they had
no endogenous production of ovarian steroids and their
endometrium was still responsive to hormone treat-
ment. Another good option would be reproductive-age
women taking gonadotropin-releasing hormone ago-
nist (GnRH-a) for endometriosis or uterine leiomyoma.
However, the use of cyclic estrogen and progestin in
these cases may offset the beneficial effect of GnRH-a
on the disease. Although natural progesterone has been
used by some groups in postmenopausal hormone
therapy, it induces irregular bleeding episodes more
frequently than progestins (synthetic progestogen).23
Therefore, progestin was used in this study. In this
study, hemodynamics in the subendometrial region
were measured because the intraendometrial vascular-
ity was very low, even in the E + P phase.
In normal menstrual cycle, VEGF mRNA has been
shown to increase relative to early proliferative-phase
expression by 1.6-, 2.0-, and 3.6-fold in midprolifera-
tive, late proliferative, and secretory endometrium,
respectively.24 This is consistent with our findings that
17-β-estradiol induced a mild, albeit statistically insig-
nificant, elevation in VEGF secretion from EEC, and
progesterone stimulated a robust and statistically sig-
nificant increase in VEGF secretion. Treatment of
human myometrial microvascular endothelial cells
(HMMEC) with VEGF has been demonstrated to
promote HMMEC proliferation and induce forma-
tion of elongated tubular structures in HMMEC, an
index of angiogenesis in vitro.25 High coexpression of
the 2 VEGF receptors, Flk-1/KDR and Flt-1, has also
been observed in capillaries during the mid-secretory
phase, suggesting that endometrial microvasculature
is more responsive to VEGF in the mid-secretory phase
than in other phases.26 Therefore, the vascularity in
mid-secretory-phase endometrium becomes higher 
because of enhanced endometrial VEGF secretion
and upregulated expression of VEGF receptors in
endometrial capillaries.
To determine the effects of estrogen and pro-
gesterone on endometrial hemodynamics in young
reproductive-age women, patients receiving frozen-
thawed embryo transfer may be recruited in the
future because they will take sequential estrogen and
progesterone following GnRH-a downregulation for
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endometrial preparation. Furthermore, since there
are 2 subtypes of PR (PR-A and PR-B), future studies
will need to ascertain which subtype of PR is responsi-
ble for mediating the effect of progesterone on endo-
metrial VEGF secretion and angiogenesis. Finally,
3D-PDA may be applied to ascertain the best luteal
phase support regimen in assisted reproductive tech-
nology by comparing endometrial hemodynamics
during the implantation window in patients taking
different luteal-phase support regimens.27
In conclusion, using 3D-PDA and VEGF deter-
mination, the present study demonstrated that prog-
esterone could stimulate VEGF secretion from EEC
and subsequently increase subendometrial vascularity
and blood flow. Therefore, uterine receptivity for the
embryo may be increased by progesterone-induced
endometrial angiogenesis. Further studies are required
to explore more applications of 3D-PDA in assisted
reproductive technology.
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